Method for production of pH stable enveloped viruses
View Patent ↗The present invention provides a method for producing pH-stable enveloped viruses wherein said viruses are used for infection of host cells under low pH conditions and for incubation with cell culture cells under conditions of low pH, as well as influenza viruses obtainable by this method which exhibit a high growth rate in cell culture, increased pH and temperature stability and which have human receptor specificity.
1. A cell-culture adapted influenza virus produced by a method comprising the steps of:
a) diluting influenza viruses in a solution having a pH of between 5.6 and 5.9;
b) infecting host cells in culture with at least one infectious virus particle, wherein:
i) the virus particle is added to said cells; and
ii) said cells and said virus particle are incubated at a pH of between 5.6 and 5.9 to provide a virus/cell complex; c) cultivating infected host cells to propagate viruses; and
d) harvesting the propagated viruses, wherein the virus retains infectivity at a pH range of between 5.6 and 5.8, wherein the influenza virus comprises a deletion or modification within the NS 1 gene of the virus, wherein the propagated viruses do not acquire mutations in the HA molecule when exposed to temperatures of up to 60° C. for 15 minutes, wherein hemagglutination activity of the propagated viruses is decreased less than fourfold compared with the source viruses, and wherein a titer above 7 log TCIDs0/ml is obtained from growth in cultured cells.
2. A composition useful for vaccination or therapy of viral disease comprising a cell-culture adapted influenza virus produced by a method comprising the steps of:
a) diluting source influenza viruses in a solution having a pH of between 5.6 and 5.9;
b) infecting host cells in culture with at least one infectious virus particle, wherein: i) the virus particle is added to said cells; and ii) said cells and said virus particle are incubated at a pH of between 5.6 and 5.9 to provide a virus/cell complex; c) cultivating infected host cells to propagate viruses; and d) harvesting the propagated viruses, and a pharmaceutically acceptable carrier or adjuvant, wherein the virus retains infectivity at a pH range of between 5.6 and 5.8, wherein the influenza virus comprises a deletion or modification within the NS 1 gene of the virus, wherein the propagated viruses do not acquire mutations in the HA molecule when exposed to temperatures of up to 60° C. for 15 minutes, wherein hemagglutination activity of the propagated viruses is decreased less than fourfold compared with the source viruses, and wherein a titer above 7 log TCIDs0/ml is obtained from growth in cultured cells.
3. The influenza virus of claim 1 , wherein the host cells used to propagate the virus are selected from the group consisting of BSC-1 cells, LLC-MK cells, CV-1 cells, CHO cells, COS cells, murine cells, human cells, HeLa cells, 293 cells, VERO cells, MDBK cells, MDCK cells, MDOK cells, CRFK cells, TCMK cells, LLC-PK cells, PK15 cells, W1-38 cells, MRC-5 cells, BHK cells, SP2/0 cells, NS0 cells, and PerC6 cells.
4. The composition of claim 2 , wherein the host cells used to propagate the viruses are selected from the group consisting of BSC-1 cells, LLC-MK cells, CV-1 cells, CHO cells, COS cells, murine cells, human cells, HeLa cells, 293 cells, VERO cells, MDBK cells, MDCK cells, MDOK cells, CRFK cells, TCMK cells, LLC-PK cells, PK15 cells, W1-38 cells, MRC-5 cells, BHK cells, SP2/0 cells, NS0 cells, and PerC6 cells.